SAN FRANCISCO and BOSTON, Sept. 17, 2025 /PRNewswire/ -- MapLight Therapeutics today announced the initiation of a Phase 2 study to evaluate the efficacy, safety and tolerability of ML-007C-MA, an investigational novel M1/M4 agonist, as a potential treatment for Alzheimer's disease psychosis (ADP). The Phase 2 VISTA study has been designed based on the results of an extensive Phase 1 development program that included 270 healthy volunteers, including 42 healthy elderly volunteers who received active drug.

"There are no FDA-approved treatments for ADP and off-label use of antipsychotics with marginal efficacy and significant safety concerns can lead to poor patient outcomes," said Christopher Kroeger, M.D., M.B.A., Chief Executive Officer and Founder of MapLight. "Muscarinic receptor agoni

See Full Page